A research team using an Alzheimer’s mouse model found that inhaled CBD, the non-intoxicating compound derived from cannabis, appeared to dampen immune pathways linked to neuroinflammation. The findings point to a possible mechanism through which CBD may influence disease processes, though the work remains at a preclinical stage and does not establish that the treatment can slow Alzheimer’s disease in people.
The study focused on the brain’s immune response, particularly pathways involving indoleamine 2,3-dioxygenase, known as IDO, and cGAS-STING, a cellular alarm system that can trigger inflammatory signalling when activated. Excessive activation of such pathways is increasingly viewed as part of the biological chain that contributes to neuronal stress, synaptic damage and cognitive decline.
Researchers found that CBD inhalation reduced markers associated with those inflammatory cascades and altered glial activity in affected brain tissue. Microglia and astrocytes, the brain’s resident immune and support cells, can help clear debris and protect neurons, but prolonged activation may worsen injury by releasing inflammatory molecules. The study suggests CBD may help shift that response towards a less damaging state.
The findings add to a growing body of work examining Alzheimer’s as a disease driven not only by abnormal protein accumulation but also by immune imbalance, oxidative stress, vascular injury and metabolic dysfunction. Amyloid and tau remain central to diagnosis and drug development, but repeated setbacks in the field have encouraged wider investigation into inflammation and other interacting pathways.
Alzheimer’s disease is the most common cause of dementia, which affected about 57 million people globally in 2021. Nearly 10 million new dementia cases are recorded each year, and the burden is rising as populations age. Alzheimer’s may account for 60 to 70 per cent of dementia cases, placing severe pressure on families, health systems and long-term care networks.
Current disease-modifying treatments have changed the Alzheimer’s landscape but have not delivered a cure. Lecanemab and donanemab target amyloid and are intended for people with early disease and evidence of amyloid build-up. Their use requires specialist diagnosis, infusion capacity and monitoring for amyloid-related imaging abnormalities, including brain swelling and bleeding. That has left a continuing need for treatments that are easier to administer, safer across broader patient groups and capable of targeting additional disease mechanisms.
CBD’s attraction lies partly in its broad biological activity. It does not produce the intoxicating effects associated with THC, the psychoactive cannabis compound, and has been studied for anti-inflammatory, antioxidant and neuroprotective properties. Laboratory research has linked CBD to modulation of cannabinoid receptors, serotonin receptors, PPAR signalling and inflammatory pathways such as TLR4/NF-kB. Those overlapping effects make it scientifically interesting but also difficult to define as a single-target medicine.
The inhaled delivery route is significant because it may allow faster systemic absorption and avoid some limitations linked to oral CBD, including variable uptake through the digestive system. Researchers involved in the work have argued that inhalation could provide a more reliable way to test CBD’s immune effects, especially in conditions where timing, dose and tissue exposure are crucial.
Caution remains essential. Mouse models reproduce selected features of Alzheimer’s disease but cannot fully capture the complexity of human dementia, which develops over many years and is shaped by age, genetics, vascular health, lifestyle and co-existing illness. Many treatments that appeared promising in animals have failed in human trials, particularly in neurodegenerative disease.
The CBD market also creates challenges for public interpretation. Commercial products vary widely in purity, dose, formulation and testing standards. Over-the-counter CBD should not be treated as equivalent to a controlled pharmaceutical preparation used in laboratory or clinical research. Older patients are also more likely to be taking multiple medicines, raising concerns about interactions, sedation, liver metabolism and falls.
The next test for the field will be carefully designed human studies that assess safety, dosing, biomarkers and cognitive outcomes. Researchers will need to show whether CBD can reduce measurable inflammation in the human brain, whether any biological change translates into clinical benefit, and whether such benefit is meaningful when compared with existing and emerging Alzheimer’s therapies.
Interest in neuroinflammation is likely to keep expanding as Alzheimer’s research moves beyond a single-cause model. CBD now sits within that broader shift, not as a proven treatment, but as one candidate in a wider search for therapies that can protect neurons by calming harmful immune activity before irreversible damage advances.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
